Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.

Cytogenetic and genome research - 1 Jan 2017

Wang Wenquan, Somers Elizabeth B, Ross Erin N, Kline J Bradford, O'Shannessy Daniel J, Schweizer Charles, Weil Susan, Grasso Luigi, Nicolaides Nicholas C

Abstract excerpt

Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha and elicits an anti-tumor response via immune effector activity. Recent studies from a global phase 3 trial in ovarian cancer patients treated with carboplatin/taxane plus farletuzumab found that the tumor-produced CA125 protein can suppress farletuzumab function via perturbing its engagement to the activating Fc-γ receptors CD32a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to CA-125 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Membrane Proteins

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Receptors, IgG

Share to Treatment Outcome

Source

Identifiers

PMID: 29041009
DOI: 10.1159/000481213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.PMID 29041009Read ↗

Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer.Semantic proximity Read ↗

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.Semantic proximity Read ↗

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.Semantic proximity Read ↗

FcγRIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk.Semantic proximity Read ↗

Effect of FCGR2A and FCGR3A variants on CLL outcome.Semantic proximity Read ↗

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerSemantic proximity Read ↗

Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.Semantic proximity Read ↗

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.Semantic proximity Read ↗

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.Semantic proximity Read ↗

FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.Semantic proximity Read ↗

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.Semantic proximity Read ↗

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.